AnxietyNCT06267313
Attention Training for COVID-19 Related Distress
A study testing Attention Bias Modification and Neutral training in people with Anxiety, run by Palo Alto University at 1 site in United States.
Trial summary
The study aims to test whether attention training (attention bias modification or attention control training) reduces distress or COVID-19 related anxiety compared to a neutral condition. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Anxiety
- What is being tested?
- Attention Bias Modification and Neutral training
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 6 participants
- Where
- 1 siteUnited States
- Study dates
- 19 Feb 2024to 9 Nov 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- COVID-19 Anxiety Syndrome Scale > 7 and/or COVID-19 related loss
Who cannot join
- Does not speak English Fluently
Trial locations and contacts
1 site in 1 country.
About this study
The study aims to test whether attention training (attention bias modification or attention control training) reduces distress or COVID-19 related anxiety compared to a neutral condition.
- Conditions
- Anxiety
- Being tested
- Attention Bias Modification, Attention Control Training, Neutral training
- Medical subject headings
- Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Attention Bias ModificationBehavioural
Training attention away from threat
Attention Control TrainingBehavioural
Training attention control
Neutral trainingBehavioural
Attention training with Neutral stimuli
| Study group | Role | What they receive |
|---|---|---|
| Attention Bias Modification | Experimental | Not described Receives: Behavioral: Attention Bias Modification |
| Attention Control Training | Active comparator | Not described Receives: Behavioral: Attention Control Training |
| Neutral Training | Placebo comparator | Not described Receives: Behavioral: Neutral training |
What is being measured
The primary outcome is the main question the study is designed to answer.
COVID-19 Anxiety Syndrome Scale
The measure is scored using a 5-point time anchored scale (0 = Not at all to 4 = Nearly every day over the last 2 weeks) and scores range between 0 and 20, with higher scores reflecting worse outcome.
Measured: 0 days
COVID-19 Anxiety Syndrome Scale
The measure is scored using a 5-point time anchored scale (0 = Not at all to 4 = Nearly every day over the last 2 weeks) and scores range between 0 and 20, with higher scores reflecting worse outcome.
Measured: 21 days
COVID-19 Anxiety Syndrome Scale
The measure is scored using a 5-point time anchored scale (0 = Not at all to 4 = Nearly every day over the last 2 weeks) and scores range between 0 and 20, with higher scores reflecting worse outcome.
Measured: 49 days
COVID-19 Anxiety Syndrome Scale
The measure is scored using a 5-point time anchored scale (0 = Not at all to 4 = Nearly every day over the last 2 weeks) and scores range between 0 and 20, with higher scores reflecting worse outcome.
Measured: 105 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2024
- Study start19 Feb 2024
- Primary completion9 Nov 2024
- Study completion9 Nov 2024
Why it stopped: Difficulty recruiting participants
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AnxietyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 6 participants (actual)
Sponsor and investigators
- Lead sponsor
- Palo Alto University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mikael Rubin, Palo Alto University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06267313
- Sponsor's protocol ID
- 2023-078-PAU
- Status last verified
- Nov 2024
- First submitted
- 17 Feb 2024
- Last updated
- 12 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: IPD will be made available with accompanying manuscript
Study at a glance
From the registry record, last updated by the sponsor on 12 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Attention Training for COVID-19 Related Distress
- ClinicalTrials.gov ID
- NCT06267313
- Acronym / sponsor ID
- 2023-078-PAU
- Conditions
- Anxiety
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Difficulty recruiting participants
- Enrolment
- 6 participants (actual)
- Lead sponsor
- Palo Alto UniversityUniversity, hospital or other
- Study start
- 19 Feb 2024 (actual)
- Primary completion
- 9 Nov 2024 (actual)
- Study completion
- 9 Nov 2024 (actual)
- First posted
- 20 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aims to test whether attention training (attention bias modification or attention control training) reduces distress or COVID-19 related anxiety compared to a neutral condition.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Attention Bias Modification | Experimental | Behavioral: Attention Bias Modification |
| Attention Control Training | Active comparator | Behavioral: Attention Control Training |
| Neutral Training | Placebo comparator | Behavioral: Neutral training |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- COVID-19 Anxiety Syndrome Scale > 7 and/or COVID-19 related loss
Key exclusion criteria (1 listed)
- Does not speak English Fluently
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Attention Bias ModificationTraining attention away from threat | Behavioural | Attention Bias Modification |
| Attention Control TrainingTraining attention control | Behavioural | Attention Control Training |
| Neutral trainingAttention training with Neutral stimuli | Behavioural | Neutral Training |
Primary outcome
COVID-19 Anxiety Syndrome Scale
Time frame: 0 days
The measure is scored using a 5-point time anchored scale (0 = Not at all to 4 = Nearly every day over the last 2 weeks) and scores range between 0 and 20, with higher scores reflecting worse outcome.
COVID-19 Anxiety Syndrome Scale
Time frame: 21 days
The measure is scored using a 5-point time anchored scale (0 = Not at all to 4 = Nearly every day over the last 2 weeks) and scores range between 0 and 20, with higher scores reflecting worse outcome.
COVID-19 Anxiety Syndrome Scale
Time frame: 49 days
The measure is scored using a 5-point time anchored scale (0 = Not at all to 4 = Nearly every day over the last 2 weeks) and scores range between 0 and 20, with higher scores reflecting worse outcome.
COVID-19 Anxiety Syndrome Scale
Time frame: 105 days
The measure is scored using a 5-point time anchored scale (0 = Not at all to 4 = Nearly every day over the last 2 weeks) and scores range between 0 and 20, with higher scores reflecting worse outcome.
Results and safety
The study was stopped early (reason given: Difficulty recruiting participants). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Nov 2024.
- Individual participant dataSharing planned: Yes. IPD will be made available with accompanying manuscript
Related trials for Anxiety
RecruitingPhase 2
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
Anxiety Disorders, Major Depressive Disorder
RecruitingObservational study
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
Mood Disorders, Anxiety Disorders
Recruiting
Modulating Anxious Coping
Anxiety Disorders
RecruitingPhase 2
Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety
Psychiatric Disorders, Anxiety Disorders
Recruiting
Digital Interventions for Relapse Prevention in Adolescence
Major Depression Disorder, ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Attention Bias Modification and Neutral training in people with Anxiety, run by Palo Alto University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 12 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Difficulty recruiting participants). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
COVID-19 Anxiety Syndrome Scale (time frame: 0 days). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Nov 2024; AzTrials last refreshed its copy on 6 Nov 2026.